Stocks in the life sciences industry have struggled to regain their sparkle following the autumn 2015 sell off triggered by Hilary Clinton’s comments on drug pricing with the NASDAQ Biotechnology Index down some 22% since the beginning of the year. Indeed both sides of the presidential race have now targeted pharmaceutical companies with Donald Trump campaigning for price negotiations between drug manufacturers and Medicare
21 Mar 2016
Lifesciences Review - Down but not out
BioMarin Pharmaceutical Inc. (0HNC:LON), 0 | Sarepta Therapeutics, Inc. (0L35:LON), 0 | hVIVO plc (HVO:LON), 28.9 | Sareum Holdings plc (SAR:LON), 10.5 | Amgen Inc. (0R0T:LON), 28,825 | Scancell Holdings Plc (SCLP:LON), 10.2 | ProMetic Life Sciences (PLI:TSE), 0 | OptiBiotix Health PLC (OPTI:LON), 21.0 | Seres Therapeutics Inc (1S9:BER), 0 | SkyePharma (SKP:LON), 0 | Oxford BioMedica plc (OXB:LON), 195 | HUTCHMED (China) Limited (HCM:LON), 264 | Blue Star Capital Plc (BLU:LON), 0.0 | Oncimmune Holdings Plc (ONC:LON), 21.1 | Verona Pharma plc Sponsored ADR (VRNA:NAS), 0
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Lifesciences Review - Down but not out
BioMarin Pharmaceutical Inc. (0HNC:LON), 0 | Sarepta Therapeutics, Inc. (0L35:LON), 0 | hVIVO plc (HVO:LON), 28.9 | Sareum Holdings plc (SAR:LON), 10.5 | Amgen Inc. (0R0T:LON), 28,825 | Scancell Holdings Plc (SCLP:LON), 10.2 | ProMetic Life Sciences (PLI:TSE), 0 | OptiBiotix Health PLC (OPTI:LON), 21.0 | Seres Therapeutics Inc (1S9:BER), 0 | SkyePharma (SKP:LON), 0 | Oxford BioMedica plc (OXB:LON), 195 | HUTCHMED (China) Limited (HCM:LON), 264 | Blue Star Capital Plc (BLU:LON), 0.0 | Oncimmune Holdings Plc (ONC:LON), 21.1 | Verona Pharma plc Sponsored ADR (VRNA:NAS), 0
- Published:
21 Mar 2016 -
Author:
Hybridan Research Team -
Pages:
4
Stocks in the life sciences industry have struggled to regain their sparkle following the autumn 2015 sell off triggered by Hilary Clinton’s comments on drug pricing with the NASDAQ Biotechnology Index down some 22% since the beginning of the year. Indeed both sides of the presidential race have now targeted pharmaceutical companies with Donald Trump campaigning for price negotiations between drug manufacturers and Medicare